CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 1188413-1188594
Annnotations
CORD-19-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T32650 | 0-181 | Sentence | denotes | Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy. |
Epistemic_Statements
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2586 | 0-181 | Epistemic_statement | denotes | Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy. |
CORD-19_Custom_license_subset
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T24 | 0-181 | Sentence | denotes | Subsequent passive immunotherapy has shown similar changes (Bapineuzimab, Elan Pharmaceuticals) raising the possibility that it may be a generic complication of Abeta immunotherapy. |